The Hindu Business Line
Patent wins may keep Suven in good health
Suven Life Sciences on Wednesday informed the bourses of the grant of one product patent each from Israel, Japan, New Zealand and Sri Lanka. The patent is for new chemical entities indicated for the treatment of disorders associated with neurodegenerative diseases such as Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, pain, Parkinson’s disease, and Schizophrenia, among others. Shareholders will closely monitor further developments.